SCHEMBL6442946

SCHEMBL6442946

COc1cc(OC)c2c[c][nH]c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.40
ALDH1A1 P00352 6/20 0.38
CYP3A4 P08684 5/20 0.38
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 3/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
HPGD P15428 2/20 0.38
GLA P06280 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
NQO2 P16083 2/20 0.37
CYP1A2 P05177 3/20 0.35
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9740234 0.80 GAA (0.38) ALDH1A1CYP3A4KDM4EHSD17B10HPGD
SCHEMBL5667763 0.75 DYRK1A (0.37) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL1539240 0.71 ABCG2 (0.41) ABCG2ALDH1A1CYP3A4KDM4EHSD17B10
SCHEMBL31513824 0.69 MEN1 (0.52) ABCG2ALDH1A1CYP3A4KDM4EHSD17B10
SCHEMBL5925752 0.69 MEN1 (0.52) ABCG2ALDH1A1CYP3A4KDM4EHSD17B10
SCHEMBL9740260 0.69 PDE3B (0.40) ABCG2ALDH1A1CYP3A4KDM4EHSD17B10
SCHEMBL577336 0.67 EHMT2 (0.48) ALDH1A1CYP3A4KDM4EHPGDNQO2
SCHEMBL29588320 0.67 ABCG2 (0.60) ABCG2ALDH1A1CYP3A4KDM4EHSD17B10
SCHEMBL21830223 0.67 CA12 (0.39) ALDH1A1CYP3A4KDM4EHSD17B10CA1
SCHEMBL533492 0.67 MEN1 (0.53) ALDH1A1KDM4EHSD17B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884802-B2 6-heteroarylphenanthridines ALTANA PHARMA AG (DE) 2005-04-26 US disclosed
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP disclosed
US-20040038979-A1 Treating airway disorders such as asthma. ALTANA PHARMA AG (DE) 2004-02-26 US disclosed
EP-1303506-A1 6-HETEROARYLPHENANTHRIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-04-23 EP disclosed
WO-2002006270-A1 NOVEL 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038979-A1 Treating airway disorders such as asthma. PTGER4, PDE4B, PDE4A ABCG2 4038/4885ALDH1A1 779/4885CYP3A4 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.